IL6 and Miyoshi myopathy: The failure rate of clinical trials, however, remains sizeable as exemplified by the limited clinical activity of the anti-IL-6 antibody siltuximab (Voorhees et al. 2013), the anti-BAFF antibody tabalumab (Raje et al. 2016, 2017), and the anti-CXCR4 antibody ulocuplumab (Ghobrial et al. 2020) in patients with relapsed/ refractory MM (RRMM).